SCHEMBL8988166

SCHEMBL8988166

CC(C)Oc1ccc(C(C)C)cc1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
CSNK2A1 P68400 2/20 0.37
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
TRPA1 O75762 1/20 0.36
PTGS1 P23219 1/20 0.36
CACNA1C Q13936 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
FABP3 P05413 2/20 0.35
FABP4 P15090 2/20 0.35
ALOX12 P18054 1/20 0.35
HTT P42858 1/20 0.35
HIF1A Q16665 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30252114 1.00 LMNA (0.38) LMNACSNK2A1GABRA1GABRB2TRPA1
SCHEMBL17861690 0.83 RXRA (0.42) LMNACSNK2A1TRPA1PTGS1CACNA1C
SCHEMBL28606337 0.83 LMNA (0.40) LMNAGABRA1GABRB2TRPA1PTGS1
SCHEMBL26879496 0.83 ALDH1A1 (0.43) LMNACSNK2A1TRPA1PTGS1CACNA1C
SCHEMBL11063120 0.83 LMNA (0.40) LMNAGABRA1GABRB2TRPA1PTGS1
SCHEMBL739698 0.81 HDAC4 (0.48) ALDH1A1GAAHDAC4HDAC8SMN1; SMN2
SCHEMBL3365122 0.79 LMNA (0.47) LMNACSNK2A1TRPA1PTGS1CACNA1C
SCHEMBL9945998 0.79 LMNA (0.45) LMNACSNK2A1TRPA1ALDH1A1SMN1; SMN2
SCHEMBL3191477 0.79 GABRA1 (0.41) LMNAGABRA1GABRB2TRPA1PTGS1
SCHEMBL28852756 0.79 LMNA (0.34) LMNAGABRA1GABRB2TRPA1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0511947-B1 Process for the purification of 2,6-diisopropyl phenol LEIRAS OY (FI) 1996-07-10 EP claimed
US-20230174444-A1 PROCESS FOR THE PREPARATION OF PROPOFOL FRESENIUS KABI ONCOLOGY LTD. (IN) 2023-06-08 US disclosed
EP-4126803-A1 PROCESS FOR THE PREPARATION OF PROPOFOL Fresenius Kabi Oncology Limited (IN) 2023-02-08 EP disclosed
WO-2021191832-A1 PROCESS FOR THE PREPARATION OF PROPOFOL FRESENIUS KABI ONCOLOGY LTD. (IN) 2021-09-30 WO disclosed
EP-2516369-B1 PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL HARMAN FINOCHEM LTD (IN) 2015-07-22 EP disclosed
US-8664452-B2 Process for preparing extra pure 2, 6-diisopropyl phenol HARMAN FINOCHEM LIMITED (US) 2014-03-04 US disclosed
EP-2522651-B1 Process for the purification of 2,6-diisopropyl phenol SIEGFRIED AG (CH) 2013-11-20 EP disclosed
US-20130072573-A1 PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL HARMAN FINOCHEM LIMITED (IN) 2013-03-21 US disclosed
WO-2013035103-A1 PHENOL C-ALKYLATION PROCESS DAVULURI RAMAMOHANRAO (IN) 2013-03-14 WO disclosed
WO-2012152665-A1 PROCESS FOR THE PURIFICATION OF 2,6-DIISOPROPYL PHENOL SIEGFRIED AG (CH) 2012-11-15 WO disclosed
EP-2522651-A1 Process for the purification of 2,6-diisopropyl phenol Siegfried AG (CH) 2012-11-14 EP disclosed
EP-2516369-A1 PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL Harman Finochem Limited (IN) 2012-10-31 EP disclosed
WO-2011161687-A1 PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL HARMAN FINOCHEM LIMITED (IN) 2011-12-29 WO disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed
EP-0511947-B1 Process for the purification of 2,6-diisopropyl phenol LEIRAS OY (FI) 1996-07-10 EP disclosed
US-5175376-A PROCESS FOR THE PURIFICATION OF 2,6-DIISOPROPYL PHENOL LEIRAS OY (FI) 1992-12-29 US disclosed
EP-0511947-A1 Process for the purification of 2,6-diisopropyl phenol LEIRAS OY (FI) 1992-11-04 EP disclosed
US-4267394-A SELECTIVE TO THE ORTHO POSITION, USING A COMPLEX OF BORON TRIFLUORIDE WITH A DIALKYL ETHER TO CATALYZE THE REACTION PHILLIPS PETROLEUM COMPANY (US) 1981-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 LMNA 488/4885CSNK2A1 1930/4885GABRA1 3775/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 LMNA 488/4885CSNK2A1 1930/4885GABRA1 3775/4885
US-20230174444-A1 PROCESS FOR THE PREPARATION OF PROPOFOL CYP3A4, CYP3A5, GABARAPL1 LMNA 3070/4885CSNK2A1 2461/4885GABRA1 18/4885
US-20130072573-A1 PROCESS FOR PREPARING EXTRA PURE 2, 6-DIISOPROPYL PHENOL CYP2B6, CYP2D6, CYP2A6 LMNA 2537/4885CSNK2A1 2496/4885GABRA1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.